Estimating the population-based incidence for sarcoma and GIST in three European regions G. Mastrangelo University of Padova.

Slides:



Advertisements
Similar presentations
MOLECULAR CARACTERISATION OF
Advertisements

The Importance of Histologic Subtype for Outcome Prediction in Primary Retroperitoneal Sarcoma: A Single-Institution Study of 675 Patients Marcus Tan,
SOFT TISSUE TUMORS Prof Hesham Saad.
Nadya Dimitrova Marieta Petkova. 13 Regional cancer registries BNCR: -Established in 1952; cases a year; million population;
Robert S. Benjamin, M.D. Department of Sarcoma Medical Oncology The SARCOMA Center Department of Sarcoma Medical Oncology The SARCOMA Center Texas Medical.
Soft Tissue Tumors Lucy H. Liu, M.D. Department of Pathology
CLINICAL CHARACTERISTICS AND OUTCOMES FOR BENIGN AND MALIGNANT SOLITARY FIBROUS TUMOR / HEMANGIOPERICYTOMA (SFT/HPC) – A SINGLE CENTER EXPERIENCE Nicholas.
1. Advantages of ultrasound imaging include:
Soft Tissue Pathology The Sort of Thing You Get in Exams!
Introduction Discussion CT abdomen 3/3/06 lightheadedness and watery diarrhea. TSH was again less than 0.01, and ACTH less than 5. AST and ALT were 240.
Janet Eary 1, Janet O'Sullivan 3, Finbarr O'Sullivan 3, E. U. Conrad 2 1. Nuclear Medicine/Radiology, University of Washington, Seattle, WA, United States.
Rarer Sarcoma Subtypes Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Boston, MA.
Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases Takuro Wada, O Sato, A Kawai, T Hasegawa Sapporo.
Procedures used by CHTN
GISTs- Gastrointestinal Stromal Tumor
Population-based Study Of Giant Cell Tumour Of The Bone In Sweden Justyna Amelio, 1 Julia Sandberg, 2 Rohini K. Hernandez, 3 Patrik Sobocki, 4 Scott Stryker,
MALIGNANT MYOEPITHELIOMA OF THE SOFT TISSUE: A MONOINSTITUTIONAL SYSTEMATIC REVIEW OF A CHALLENGING DIAGNOSIS AND ANALYSIS OF CLINICAL FEATURES. Marco.
November 2006 Phase II Study of Dasatinib in Advanced Sarcoma SARC 009 Coordinating site: University of Michigan.
Piya Kiatisevi 1, Torsten Nielsen 2, Malcolm Hayes 2, Peter L Munk 3, Amy E LaFrance 4, Paul W Clarkson 4, Bassam A Masri 4 1 Orthopaedic Oncology Lerdsin.
EQA006 Preliminary analysis. Case 1 44 year old female with multiple subcutaneous nodules in hypo-chondral region. IMMUNOHISTOCHEMISTRY: Strong positive.
Challenges in the Treating of Bone and Soft Tissue Sarcomas Margaret von Mehren, MD Director Sarcoma Oncology Fox Chase Cancer Center Philadelphia, PA.
Soft Tissue Tumors Academy of Pathology and Laboratory Medicine of Puerto Rico April 2013 Bruce Horten, M.D. Medical Director Integrated Oncology, New.
Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,
Incidence of Childhood Cancer. What is cancer ? Uncontrolled growth of cells Are these cancer cells abnormal? No, but their behaviour is.
SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME
Bone and soft tissue tumors Imad Fadl-Elmula Al Neelain University.
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
Systemic Pathology. Neoplasia -Abnormal cell growth.
A Metabolic Approach to Sarcoma Therapy
RARECARE project Data quality and supplementary information Granada, March 25 th 2009 Andalusian School of Public Health.
Sarcomas Perspectives and Background. Sarcomas: Themes Sarcomas are a heterogeneous collection of diseases and families of diseases –Individual diseases/families.
Factors Influencing Sarcoma Referral and Treatment William G. Ward, Matthew T. Cline, Fred J. Dorey* Wake Forest University Health Sciences, Winston-Salem,
Prognostic value of myogenic differentiation in adult soft tissue sarcomas (STS) A study of 855 cases from the French Sarcoma Group N Stock, MC Chateau,
Symposium 2: Sarcoma of the Year – Synovial Sarcoma Peter Reichardt HELIOS Klinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg.
Trabectedin contribution to the treatment of sarcomas Pr JY Blay Centre Leon Berard, Lyon EORTC.
MEASURING CLINICAL EFFICACY IN PHASE II TRIALS Response: Karnofsky, WHO, RECIST Event rate: progression free/survival Time to event: progression/survival.
NEOPLASIA Def.: persistent abnormal
Phase II Study of Dasatinib (BMS ) in Advanced Sarcomas and Chordoma Coordinating Center: U Michigan.
1 Sarcoma Ages >= ** Analytic - Initially Diagnosed and/or received all or part of 1st course treatment at.
Malignancy Grade and Histologic Subtype of Primary Retroperitoneal Sarcoma (RPS) are Predictive of Pattern of Recurrence: a Large Retrospective Study from.
Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.
Incidence and prognosis of hepatocellular adenoma in Denmark Lars Bossen Departments of Hepatology and Gastroenterology and Clinical Epidemiology Aarhus.
Cutaneous Carcinosarcoma Katy H. Goldsborough, William B. Laskin, Jeffrey D. Wayne, Mark Agulnik Department of Medicine, Division of Hematology/ Oncology,
Institut Bergonié 1 MULTICENTRIC EVALUATION OF THE FRENCH SURGICAL SYSTEM IN SOFT TISSUE SARCOMA (STS). E. Stoeckle, S. Bonvalot, JY Blay, L. Guillou,
12 th Annual CTOS Meeting 2006 AP23573 Induced Long-term Stability in 2 Patients with Desmoplastic Small Round Cell Tumor (#561) Scott Schuetze, Warren.
Local Recurrence Growth Rate Predicts Outcome In Locally Recurrent Retroperitoneal Liposarcoma James Park, MD, Li-Xuan Qin, PhD, Francesco Prete, MD Murray.
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
Priority of SARC studies for selected sub-types. Eligibility SARC 003 –Gem/docetaxel –Osteo/Ewings < 2 prior regimens –Chondrosarcoma 0-X prior regimens.
Soft tissue Tumors II. Lecture 36 : Soft tissue tumors II At the end of session the student should be able to: Discuss benign and malignant fibrohistiocytic.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
Current Concepts in Pathology of Soft Tissue Sarcoma Nuzhat Husain & Nidhi Verma Indian J Surg Oncol Received: 16 December 2011 / Accepted: 2 February.
RARECARE project Proposal for improving data quality on rare cancers with high priority Granada, March 25 th 2009 Andalusian School of Public Health.
Pathologic Features of Prognostic Significance in Primary Retroperitoneal Liposarcoma Amanda J. Cannell 1, Sally M. Burtenshaw 1, Martin E. Blackstein.
CONTRIBUTION OF CHROMOSOME BANDING AND MOLECULAR CYTOGENETIC ANALYSES FOR THE DIAGNOSIS OF SOFT TISSUE AND BONE TUMORS OVER A 6-YEAR-PERIOD Manuel Teixeira,
University of Pennsylvania Department of Orthopaedic Surgery Joseph King, Eileen Crawford, Abass Alavi, Arthur Staddon, Lee Hartner, Richard Lackman and.
Genetic Testing in Sarcoma: Current practice and future perspectives
LG Fibromyxoid Sarcoma Proliferative Myositis Solitary Fibrous Tumor
Soft Tissue Tumors Ali AlGhamdi.
Table 3. Age Distribution of Solid Malignant Tumours in Children
Soft Tissue Sarcoma (All Subtypes Combined): 2010
Discordance of histo-pathological diagnosis of patients with soft tissue sarcoma referred to tertiary care center. Rastogi,S., Aggarwal, A., Soti, K.,
Johns Hopkins Hospital Cancer Registry
Department of Laboratory Medicine, CORE Diagnostics, Gurgaon, India
Soft Tissue Sarcoma (All Subtypes Combined):
Childhood Cancer Statistics, England, Annual report 2018.
SOFT TISSUE & SKELETAL SYSTEM LABORATORY
Alexander C.L. Chan 3 November 2018
Oncologist-Directed Solutions for Cancer Therapy & Drug Discovery
RETROPERITONEAL NON-FUNCTIONING PARAGANGLIOMA: A DIFFICULT TUMOR TO DIAGNOSE AND TREAT GENERAL SURGERY DEPARTMENT I HMIMV.
Presentation transcript:

Estimating the population-based incidence for sarcoma and GIST in three European regions G. Mastrangelo University of Padova

Background The challenges of sarcomas: sarcomas are rare tumors, but include more than 50 different histological subtypes incidence of sarcomas is grossly underestimated since the International Classification of Disease attributes visceral sarcomas to the organ of origin. in late 2002, the World Health Organization (WHO) published a new classification of soft tissue tumors studies have shown that in about 10% of cases there is a discrepancy: one pathologist renders a diagnosis and another pathologist looks at the same material and renders a different opinion

Scope To estimate: the population-based morphologic specific incidence of sarcoma in Veneto, Rhone-Alpes, Aquitaine, in 2007-2008, using the 2002 WHO classification. the survival rate in the time window 2007 to 2011

Methods All the pathology laboratories were informed and agreed to participate into the study A clinical monitor visited each laboratory to collect any information on sarcoma cases (but in Rhone-Alpes cases were prospectively notified by the pathologists The inclusion criteria were checked, the cases were reviewed and some were excluded after the review

Subjects Cases are subjects: of both gender, any age, resident and treated in the same region (Veneto, Rhone-Alpes, or Aquitaine) with histologically proven malignant sarcoma diagnosed as first cancer in one year of observation Data for estimating the rates Veneto Rhone-Alpes Aquitaine Cases 2007 2005 Population

Main characteristics of cases Veneto Rhone-Alpes Aquitaine Overall number 300 342 170 With expert review (%) 58% 94% 100% Tumor resection (%) 86% ? 77% Women (%) 45% 50% 48% Age (mean  SD) 6217 6118 6020

Sarcomas more frequent in children (0-19 years) with sporadic cases in adults: Ewing sarcoma Rhabdomyosarcoma Synovial sarcoma

Sarcomas with sporadic cases in children and more frequent in adults Dermatofibrosarcoma protuberans Liposarcoma Leiomyosarcoma

Sarcomas consistently more frequent in men: Kaposi sarcoma Liposarcoma Dermatofibrosarcoma protuberans Myxofibrosarcoma

Sarcomas consistently more frequent in women: Uterine leiomyosarcoma and angiosarcoma

Sarcomas with no consistent pattern in relation to gender: GIST Sarcoma NOS Leiomyosarcoma Pleomorphic sarcoma (MFH)

Sarcomas with few or very few cases: Fibromyxoid sarcoma MPNST Solitary malignant fibrous tumor Fibrosarcoma Other sarcomas

Other sarcomas (with less than 5 cases) Clear cell sarcoma Dedifferentiated aggressive angiomyxoma Desmoplastic round cell tumor Epithelioid haemangioendothelioma Epithelioid sarcoma Extrarenal rhabdoid tumour Extraskeletal chondrosarcoma Extraskeletal myxoid chondrosarcoma Haemangiopericitoma Inflammatory myofibroblastic tumor Intimal sarcoma Malignant epitelioid angiomyolipoma Malignant myopericitoma Melanocitic schwannoma Myofibroblastic sarcoma Myxoinflammatory fibroblastic sarcoma Pecomas Pleomorphic sarcoma with myogenic differentiation